See more : Shuang Yun Holdings Limited (1706.HK) Income Statement Analysis – Financial Results
Complete financial analysis of DexCom, Inc. (DXCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DexCom, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- iCatch Technology, Inc. (6695.TWO) Income Statement Analysis – Financial Results
- Givot Olam Oil Exploration-Limited Partnership(1993) (GOOXF) Income Statement Analysis – Financial Results
- Lekoil Limited (LEK.L) Income Statement Analysis – Financial Results
- Orion Metals Limited (ORM.AX) Income Statement Analysis – Financial Results
- Tiga Gaming Inc. (6536.TWO) Income Statement Analysis – Financial Results
DexCom, Inc. (DXCM)
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.62B | 2.91B | 2.45B | 1.93B | 1.48B | 1.03B | 718.50M | 573.30M | 402.00M | 259.20M | 160.00M | 99.90M | 76.27M | 48.63M | 29.69M | 9.84M | 4.63M | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33B | 1.03B | 768.00M | 646.60M | 544.50M | 367.70M | 226.40M | 194.90M | 123.60M | 82.90M | 59.90M | 53.30M | 40.42M | 30.19M | 26.03M | 15.37M | 12.74M | 10.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.29B | 1.88B | 1.68B | 1.28B | 931.50M | 663.90M | 492.10M | 378.40M | 278.40M | 176.30M | 100.10M | 46.60M | 35.84M | 18.44M | 3.66M | -5.53M | -8.11M | -8.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 63.19% | 64.72% | 68.63% | 66.44% | 63.11% | 64.36% | 68.49% | 66.00% | 69.25% | 68.02% | 62.56% | 46.65% | 47.00% | 37.92% | 12.33% | -56.20% | -175.25% | -405.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 505.80M | 484.20M | 604.20M | 359.90M | 273.50M | 417.40M | 185.40M | 156.10M | 137.50M | 69.40M | 44.80M | 39.50M | 30.75M | 23.23M | 14.29M | 19.63M | 16.13M | 19.42M | 26.77M | 12.47M | 8.93M | 6.31M | 5.04M | 2.90M |
| General & Administrative | 1.00B | 867.20M | 684.10M | 544.20M | 482.60M | 408.80M | 327.30M | 274.30M | 194.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 180.80M | 133.00M | 126.40M | 76.50M | 33.10M | 24.00M | 21.90M | 11.90M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 325.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.19B | 1.00B | 810.50M | 620.70M | 515.70M | 432.80M | 349.20M | 286.20M | 198.00M | 128.40M | 84.20M | 62.80M | 49.94M | 40.51M | 35.20M | 27.67M | 22.44M | 21.11M | 5.66M | 1.60M | 1.25M | 0.00 | 1.69M | 1.11M |
| Other Expenses | 0.00 | 7.50M | -1.70M | 0.00 | 0.00 | 0.00 | 3.40M | -700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.69B | 1.49B | 1.41B | 980.60M | 789.20M | 850.20M | 534.60M | 442.30M | 335.50M | 197.80M | 129.00M | 102.30M | 80.69M | 63.73M | 49.49M | 47.30M | 38.57M | 40.53M | 32.43M | 14.07M | 10.18M | 6.31M | 6.72M | 4.01M |
| Cost & Expenses | 3.02B | 2.52B | 2.18B | 1.63B | 1.33B | 1.22B | 761.00M | 637.20M | 459.10M | 280.70M | 188.90M | 155.60M | 121.11M | 93.92M | 75.53M | 62.67M | 51.30M | 51.49M | 32.43M | 14.07M | 10.18M | 6.31M | 6.72M | 4.01M |
| Interest Income | 135.00M | 18.00M | 1.70M | 16.10M | 26.40M | 2.40M | 3.30M | 400.00K | 0.00 | 0.00 | 0.00 | 100.00K | 107.00K | 95.00K | 354.00K | 1.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.30M | 18.60M | 102.00M | 84.70M | 60.30M | 22.70M | 12.80M | 700.00K | 400.00K | 800.00K | 900.00K | 200.00K | 11.00K | 1.55M | 8.05M | 7.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 186.00M | 155.90M | 101.90M | 67.10M | 48.70M | 29.10M | 16.10M | 15.00M | 10.80M | 8.40M | 7.00M | 6.60M | 3.76M | 2.44M | 2.37M | 3.58M | 3.33M | 2.70M | 1.07M | 935.49K | 353.55K | 0.00 | 0.00 | 0.00 |
| EBITDA | 916.70M | 565.30M | 377.50M | 376.80M | 213.20M | -74.70M | -19.70M | -49.20M | -46.30M | -13.10M | -21.90M | -49.00M | -40.98M | -51.19M | -43.11M | -49.79M | -43.34M | -46.62M | -29.70M | -13.13M | -9.83M | -6.31M | -6.72M | -4.01M |
| EBITDA Ratio | 25.31% | 14.33% | 11.33% | 19.86% | 11.14% | -10.06% | -4.98% | -11.20% | -14.20% | -8.29% | -13.69% | -49.05% | -53.87% | -70.79% | -146.36% | -500.90% | -936.76% | -2,148.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 597.70M | 391.20M | 175.40M | 299.50M | 142.30M | -186.30M | -42.50M | -63.90M | -57.10M | -21.50M | -28.90M | -55.70M | -44.84M | -45.29M | -45.83M | -52.83M | -46.68M | -49.32M | -32.43M | -14.07M | -10.18M | -6.31M | -6.72M | -4.01M |
| Operating Income Ratio | 16.50% | 13.44% | 7.16% | 15.54% | 9.64% | -18.06% | -5.92% | -11.15% | -14.20% | -8.29% | -18.06% | -55.76% | -58.80% | -93.13% | -154.36% | -536.97% | -1,008.77% | -2,273.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 112.70M | -400.00K | -9.00M | -74.50M | -38.10M | 59.80M | -6.10M | -1.00M | -400.00K | -800.00K | -900.00K | -100.00K | 97.00K | -9.88M | -7.69M | -2.36M | 798.00K | 2.72M | -30.86B | 120.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 710.40M | 390.80M | 173.90M | 225.00M | 104.20M | -126.50M | -48.60M | -64.90M | -57.50M | -22.30M | -29.80M | -55.80M | -44.75M | -55.17M | -53.52M | -55.18M | -45.88M | -46.60M | -30.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 19.61% | 13.43% | 7.10% | 11.68% | 7.06% | -12.26% | -6.76% | -11.32% | -14.30% | -8.60% | -18.63% | -55.86% | -58.67% | -113.45% | -180.26% | -560.93% | -991.53% | -2,147.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 168.90M | 49.60M | 19.20M | -268.60M | 3.10M | 600.00K | 1.60M | 700.00K | 100.00K | 100.00K | 0.00 | -1.30M | -97.00K | 9.88M | 0.00 | 2.36M | 0.00 | 253.00 | -30.86B | -120.65K | -270.00K | 7.71M | 6.27M | 3.97M |
| Net Income | 541.50M | 341.20M | 154.70M | 493.60M | 101.10M | -127.10M | -50.20M | -65.60M | -57.60M | -22.40M | -29.80M | -54.50M | -44.75M | -55.17M | -53.52M | -55.18M | -45.88M | -46.60M | -30.77M | -13.95M | -9.91M | -7.71M | -6.27M | -3.97M |
| Net Income Ratio | 14.95% | 11.73% | 6.32% | 25.62% | 6.85% | -12.32% | -6.99% | -11.44% | -14.33% | -8.64% | -18.63% | -54.55% | -58.67% | -113.45% | -180.26% | -560.93% | -991.53% | -2,147.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.44 | 0.88 | 0.40 | 1.31 | 0.28 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 | -0.10 | -0.20 | -0.17 | -0.24 | -0.30 | -0.47 | -0.41 | -0.43 | -0.41 | -1.53 | -1.14 | -0.94 | -0.83 | -0.57 |
| EPS Diluted | 1.30 | 0.80 | 0.36 | 1.27 | 0.27 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 | -0.10 | -0.20 | -0.17 | -0.24 | -0.30 | -0.47 | -0.41 | -0.43 | -0.41 | -1.53 | -1.14 | -0.94 | -0.83 | -0.57 |
| Weighted Avg Shares Out | 386.00M | 389.40M | 386.90M | 377.60M | 364.40M | 352.80M | 345.20M | 334.40M | 319.20M | 300.80M | 284.40M | 274.80M | 262.40M | 227.60M | 177.39M | 117.95M | 113.25M | 108.94M | 75.78M | 9.14M | 8.68M | 8.18M | 7.59M | 6.91M |
| Weighted Avg Shares Out (Dil) | 425.50M | 427.50M | 428.80M | 390.00M | 369.20M | 352.80M | 345.20M | 334.40M | 319.20M | 300.80M | 284.40M | 274.80M | 262.40M | 227.60M | 177.39M | 117.95M | 113.25M | 108.94M | 75.78M | 9.14M | 8.68M | 8.18M | 7.59M | 6.91M |
Class Action Filed Against DexCom, Inc. (DXCM) - October 21, 2024 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
DXCM Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA / ACCESSWIRE / October 20, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. ("DexCom") (NASDAQ:DXCM) on behalf of investors who...
FINAL REMINDER DXCM DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts DexCom, Inc. Investors to Participate in the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) and...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or...
RLF Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom...
DXCM DEADLINE UPDATE: DexCom, Inc. Investors are Alerted of Monday, October 21 Court Deadline; Contact BFA Law about Securities Fraud Class Action
NEW YORK, NY / ACCESSWIRE / October 18, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested...
DXCM Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District...
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
LOS ANGELES , Oct. 18, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Class...
Faruqi & Faruqi Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESSWIRE / October 18, 2024 / If you...
Source: https://incomestatements.info
Category: Stock Reports